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Abstract 
The most important type I interferons (IFNs) are IFN-α and IFN-β, which are mainly 
produced after a viral infection and bind to a type II cytokine receptor, consisting of an 
IFNAR1 and IFNAR2 receptor chain. Type I IFNs have been shown to bridge the innate and 
the adaptive immune response by activating especially dentritic cells (DCs). Recently, IFNs 
have also been identified as critical coordinators of the interaction between the immune 
system and tumor cells.  
In this study we investigated the impact of type I IFN signaling on B cell leukemia in mice. 
Our tumor model is the Abelson-induced leukemia. The human correlate of this disease is the 
bcr-abl induced chronic myeloid leukemia (CML) and acute lymphoid leukemia (ALL). Our 
laboratory has shown previously that IFNAR1-/- and IFN-β-/- mice succumb to B-lymphoid 
leukemia significantly faster than wild type controls after challenge with the Abelson 
oncogene. In addition, transplantation of Abelson transformed IFNAR1 and IFN-β knock out 
bone marrow cell lines into Rag2-/- mice lead to a faster progression of B-lymphoid leukemia 
than wt v-abl transformed cells.  
Based on these findings we addressed the question whether the observed phenotype was due 
to a tumor cell intrinsic effect or due to a defective immune response. To do so, we crossed 
IFNAR1fl/fl mice with CD19cre+ mice to delete the IFNAR1 receptor chain of the type I IFN 
receptor specifically in B-lymphocytes. We infected newborn IFNAR1fl/flCD19cre+ mice and 
their wild type littermates with A-MuLV and found that IFNAR1fl/flCD19cre+ mice disease 
slightly faster than IFNAR1fl/flCD19cre- mice. This suggests that the faster progression of B-
lymphoid leukemia is due to a tumor cell intrinsic effect. However, we could not confirm the 
hypothesis that wild type animals are less prone to develop Abelson-induced leukemia 
because wild type tumor cells produce constitutive low levels of IFN-β  and thereby decelerate 
their own proliferation. When wt and IFNAR1-/- v-abl transformed cells were transplanted 
into Rag2-/-γc-/- mice both groups of recipient mice succumbed to leukemia with comparable 
latency. This finding indicates that impaired type I IFN signaling also influences Nk cell 
effector functions. During this study we also stroke a new path to elucidate the role of type I 
IFN signaling in v-abl induced leukemia. We started to analyze the impact of type I IFN 
signaling in angiogenesis and could show that tumor cells deficient in type I IFN signaling 
have an increased VEGF expression level and lead to faster migration of endothelial cells in 
scratch assays.  
Taken together, this work demonstrates the importance of type I IFN signaling in Abelson-
induced leukemia. The obtained data suggest that the combination of a tumor cell intrinsic 
effect and a defect in immune response is responsible for higher susceptibility to Abelson-
induced leukemia in mice with impaired type I IFN signaling.  
Zusammenfassung 
Die wichtigsten Typ I Interferone sind IFN-α und IFN-β, welche hauptsächlich nach 
Virusinfektionen produziert werden und an den Typ II Zytokinrezeptor binden, der aus einer 
IFNAR1 und einer IFNAR2 Rezeptorkette besteht. Darüber hinaus wurde gezeigt, dass Typ I 
Interferone die angeborene und die adaptive Immunantwort verbinden, vor allem in dem sie 
dentritische Zellen aktivieren. Erst kürzlich hat man herausgefunden, dass Interferone 
wichtige Koordinatoren in der Interaktion von Immunsystem und Tumorzellen sind.  
In dieser Studie haben wir den Einfluss von Typ I Interferon signaling auf B-Zell Leukämie in 
Mäusen untersucht. Das humane Korrelat dazu ist der replikationsinkompetente Abelson 
Mausleukämie Virus (A-MuLV). In unserem Labor wurde gezeigt, dass IFNAR1-/- und IFN-
β-/- Mäuse signifikant schneller an B-lymphoider Leukämie sterben als die wildtyp 
Kontrollen nach einer einer Virusinfektion von neugeborenen Mäusen. Außerdem führt die 
Injektion von v-abl transformierten IFNAR1 und IFN-β knock out Knochenmarkzelllinien in 
Rag2-/- Mäuse zu einem schnelleren Fortschritt der B-lymphoiden Leukämie, als die 
Injektion von wildtyp v-abl transformierten Zellen.  
Basierend auf diesen Erkenntnissen, haben wir uns die Fragen gestellt ob der beobachtete 
Phänotyp auf Grund eines Tumorzell intrinsischen Effektes oder auf Grund eines Defektes der 
Immunantwort herbeigeführt wird. Um diese Fragen zu beantworten, haben wir IFNAR1fl/fl 
Mäuse mit CD19cre+ Mäuse gekreuzt, um die IFNAR1 Rezeptorkette vom Typ I 
Interferonrezeptor speziell auf B-Lymphozyten zu deletieren. Wir haben neugeborene 
IFNAR1fl/flCD19cre+ Mäusen und ihren Wildtyp Wurfgeschwister mit A-MuLV infiziert und 
herausgefunden, dass IFNAR1fl/flCD19cre+ Mäuse etwas früher sterben als 
IFNAR1fl/flCD19cre- Mäuse. Dies deutet darauf hin, dass der schnellere Fortschritt der B-Zell 
Leukämie auf einem Tumorzell intrinsischen Effekt basiert. Jedoch konnten wir die 
Hypothese, dass wt Tiere weniger anfällig sind eine Abelson-induzierte Leukämie zu 
entwickeln, weil wt Tumorzellen ein konstitutives geringes Level an INF-β produzieren, nicht 
bestätigen. Transplantationsversuche mit Rag2-/-γc-/- Mäusen als Empfänger, haben gezeigt, 
dass Mäuse, injiziert mit wt Tumorzellen vergleichbar schnell an B-Zell Leukämie gestorben 
sind, als Mäuse die mit Knockout Tumorzellen injiziert wurden. Dieses Ergebnis liefert den 
Hinweis, dass beeinträchtigtes Typ I Interferon signaling die Effktor- Funktionen von Nk 
Zellen beeinflusst. Während dieser Studie haben wir außerdem einen neuen Weg 
eingeschlagen um die Rolle von Typ I Interferon signaling während einer v-abl induzierten 
Leukämie aufzuklären. Wir haben begonnen die Auswirkung von Typ I Interferonen auf die 
Angiogenese zu analysieren und konnten zeigen, dass Tumorzellen mit fehlerhaften Typ I 
Interferon signaling verstärkt VEGF expremieren und dazu führen, dass Endothelzellen 
schneller zusammen wachsen in einem Scratch assay.  
Zusammenfassend zeigt diese Arbeit die Wichtigkeit von Typ I Interferon signaling in der 
Tumorentstehung. Unsere Daten liefern einen Hinweis darauf, dass die Kombination eines 
Tumorzell intrinsischen Effektes und eines Defektes in der Immunantwort vielleicht 
verantwortlich ist für die höhere Anfälligkeit für Abelson-induzierte Leukämie in Mäusen mit 
beeinträchtigtem Typ I Interferon signaling. 
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1. Introduction 
1.1. Type I Interferons 
50 years ago, interferons (IFNs) were originally described as soluble secreted molecules 
capable of interfering with viral infections (Aboagye-Mathiesen et al., Isaacs et al., 1957). 
IFNs are pleiotropic cytokines with important pro-inflammatory functions needed in the 
defense against bacterial and viral infections. Moreover, it has been realized that type I IFNs 
play a crucial role in promoting anti-tumor effects. The importance of type I IFNs in cancer 
immunosurveillance, immune homeostasis and immuno suppression has been shown 
previously and is well documented. 
Up to now, several different IFNs have been described. They are divided into two main 
classes: type I IFN and type II IFN. IFN-γ is the only member of type II IFNs, whereas 
several type I IFNs have been discovered, including IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ξ and 
IFN-ω (Pestka et al., 2004). 
IFN-α is a family of approximately twenty structurally related proteins encoded by different 
genes. IFN-β is a single protein. All virally infected cells produce type I IFNs. IFN-α/β bind 
to the same receptor, called type I IFN receptor, and induce similar biologic responses. The 
receptor belongs to the type II cytokine receptor family, which consists of two heterologous 
polypeptides that are called IFNAR1 and IFNAR2. Binding of IFN-α/β activates the 
JAK/STAT pathway, which in turn activates transcription of the respective target genes 
(Kotenko et al., 2003). 
Two different ways are known how virally infected cells can produce type I IFNs: 1. Specific 
pathogen-associated molecular patterns expressed by viruses and microbes are recognized by 
Toll-like receptors (TLRs) (Tanabe et al., 2003) (Akira et al., 2003), which is also called the 
TLR-dependent pathway. 2. The TLR-independent pathway is mediated by RNA helicases 
called retinoic acid inducible gene-I (RIG-I) and melanoma differentiation associated gene 5 
(Mda5) (Yoneyama et al., 2005, Rothenfusser et al., 2005) which recognize cytoplasmic viral 
RNA.  
Figure 1 demonstrates the complex signaling pathways, which are activated upon a viral 
infection leading to the transcription of IFN-α/β. Either the TLR-dependent or TLR-
independent recognition pathway activates IFN response factor (IRF)- kinases (IKK related 
Introduction 
2 
kinases) by phosphorylation of the transcription factors IRF-3 and IRF-7. In the early phase of 
an infection, only the constitutively expressed IRF-3 resides in the cytoplasm, which enters 
the nucleus after phoshorylation. In the nucleus, IRF-3 associates with co-activators and binds 
to IRF binding elements (or PRDI elements) within the IFN-β promoter. The binding leads to 
the expression of IFN-β, which in turn triggers the transcription of the transcription factor 
IRF-7. The IRF-7 gene contains ISRE sites (IFN stimulated response element) that respond to 
the IFN stimulated gene factor 3 (ISGF3), which is a tetrameric transcriptional activator 
consisting of signal transducer and activator of transcription 1 (STAT1), STAT2 and IRF9. 
This ISGF3-dependent IRF-7 transcription amplifies transcription of IFN-α and IFN-β genes 
followed by enhanced production of IFN-α and IFN-β (Marie et al., 1998, Sato et al., 1998). 
Thus it is called the positive feedback regulation of IFNs. 
 
Figure 1. Summary of recognition pathways and downstream signaling leading to IFN-β  production. 
Either TLRs (TLR3, TLR7 and TLR9) or cytoplasmic helicases (RIG-I and Mda5) are activated after a viral 
infection, which leads to the activation of several kinases and finally to the phosphorylation of transcription 
factors belonging to the IRF family (IRF-3 and IRF-7). Phosphorylated IRFs enter the nucleus and activate IFNβ 
transcription. (Figure taken from Oncogene, Hiscott et al., 2006).  
Deonarain and his colleagues showed that mice deficient in the IFN-β gene were highly 
susceptible to a more aggressive tumor growth. It has been also shown that IFN-β-/- mice 
have reduced levels of circulating mature B and myeloid lineage cells. Moreover it was 
reported that in IFN-β deficient mice not only virally induced IFN-β, but also IFN-α 
production is abolished (Deonarain et al., 2003) (Erlandsson et al., 1998), indicating that the 
expression of IFN-α genes is at least partially dependent on IFN-β expression. The studies 
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revealed that IFN-α can be induced by IFN-β, but IFN-β cannot be induced by IFN-α (Asano 
et al., 1990). 
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1.2. Type I IFN and the JAK/STAT Pathway 
One very well studied pathway by which cytokines transduce signals and activate 
transcription of target genes involves kinases called Janus kinases (JAKs) and transcription 
factors called signal transducers and activators of transcription (STATS). The JAK/STAT 
pathway is important for cell-development, cell-differentiation and host defense mechanisms. 
The discovery of the JAK/STAT pathway resulted from biochemical and genetic analyses of 
IFN signaling (Darnell et al., 1994).  
Up to now there are four different JAKs known (JAK1, JAK2, JAK3, TYK2) that are named 
after the two-headed Roman god because of the presence of two kinase domains – only one of 
which is active. JAKs are non-receptor tyrosine kinases loosely attached to the cytoplasmatic 
domains of their respective cytokine receptors. Upon ligand binding, two receptor molecules 
are brought together and the receptor-associated JAKs are activated by transphosphorylation, 
and they phosphorylate tyrosine residues in the cytoplasmic domain of the receptors. 
Cytosolic STAT proteins bind via their Src homology 2 (SH2) region to the phosphotyrosine 
residues of the receptor and get activated. The SH2 domain of one STAT can now bind the 
phosphotyrosine residue of another STAT and the dimer dissociates from the receptor. As a 
result, STAT dimers migrate to the nucleus, where they bind promotor regions of cytokine-
responsive genes and activate transcription. Janus kinases are structurally divided into an N-
terminal Ferm domain that binds to the respective cytokine receptor chain, followed by a SH2 
domain, a catalytically inactive pseudokinase domain and a C-terminal tyrosine kinase 
domain (O'Shea et al., 2002) (Imada et al., 2000), as shown in Figure 2.  
So far there are 7 different STAT proteins known (STAT1-STAT4, STAT5A, STAT5B, 
STAT6). STAT1 and STAT2 were the first members identified as mediators of the cellular 
response to IFNs. Each STAT protein responds to different extracellular stimuli and leads to 
another gene transcription, but they share a characteristic structure. The N-terminus is 
important for STAT dimerisation, followed by a coiled-coil (cc) domain that is involved in 
protein-protein interactions. STATs bind to the DNA in the nucleus via their DNA-binding 
domain (DBD) and to cytokine receptors and other STAT proteins, respectively via their SH2 
domain. As shown in Figure 2B STATs have a conserved single tyrosine residue that is the 
site of phosphorylation after activation. The C-terminus is called the transactivation domain 
(TAD) and plays an important role in transcriptional activation (Reich et al., 2006).  
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Figure 2. Proteins involved in type I IFN signaling. (A) JAK consists of a N-terminal FERM domain followed 
by a SH2 domain and 2 kinase domains (Yamaoka et al., 2004) (B) The structure of STAT1 and STAT2 shows 
characteristic coiled- coil domains, followed by a DNA-binding domain and a SH2 domain. Together with IRF9 
they form the ISGF3 complex that enters the nucleus (Nancy C. Reich, Ling Liu, 2006).  
As mentioned above, IFN-α and IFN-β are produced upon viral infections. In order to 
mediate an early innate immune response, the cytokines bind to the type I interferon receptor 
that is composed of IFNAR1 and IFNAR2. IFNAR1 is associated with TYK2 and IFNAR2 
with JAK1 that phosphorylate STAT1 and STAT2. Phosphorylated STAT2 and STAT1 
proteins form STAT1/STAT2 heterodimers and dissociate from the receptor. Binding of the 
transcription factor IRF9 in the cytosol enables them to enter the nucleus as the ISGF3 
complex. In the nucleus, the ISGF3 complex binds to IFN stimulated response elements 
(ISRE) and activates transcription of target genes, which are called IFN stimulated genes 
(ISGs) (Dunn et al., 2006). In addition STAT1 homodimers are also formed and enter the 
nucleus, where they bind to promoters at the IFNγ-activated site (GAS) (Decker et al., 1991) 
(shown in Figure 3). 
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Figure 3. Scheme of type I IFN signaling. Binding of IFN-α/β leads to receptor dimerisation and 
phosphorylation of JAKs, which in turn phosphorylate STAT1 and STAT2. Phosphorylated STAT proteins form 
heterodimers and bind IRF9, forming the ISGF3 complex. The ISGF3 complex further enters the nucleus and 
binds to ISRE elements thereby starting gene transcription. In addition STAT1 homodimers also form which 
enter the nucleus and bind to promoters at the IFNγ-activated site (GAS) (This figure was taken and modified 
from Dunn et al., 2006). 
Binding of ISGF3 leads to transcription of IRF-3 and IRF-7 maintaining the auotcrine 
positive feedback loop as mentioned above. Different genes involved in dentritic cell 
activation, T-cell survival, natural killer-cell activation, chemokine expression, lymph-node 
retention and anti-proliferative and anti-viral effects are expressed following type I IFN 
signaling. Binding of STAT1 homodimers to GAS sites is crucial for IRF-1 expression as 
well as the expression of different genes involved in MHC class I and class II regulation, 
chemokine expression, Treg-cell inhibition, TH1-cell differentiation, CTL activation and 
differentiation and antiproliferative effects (Dunn et al., 2006). 
Several controlling mechanisms of type I IFN signaling are involved in appropiate signal 
transduction: (1.) SHP-mediated de-phosphorylation of the receptor complex, including JAKs 
and STATs, (2.) SOCS mediated inhibition of the JAKs, (3.) PIAS mediated inhibition of 
STATs and (4.) proteasomal degradation of the JAKs are also required for proper type I IFN 
signaling (also shown in Figure 3) (Dunn et al., 2006).  
During this study we used IFNAR1-/- and IFN-β-/- mice, impaired in different steps of type I 
IFN siganling. Different studies have shown that IFNAR1-/- as well as IFN-β-/- mice were 
extremely susceptible to different types of viral infections. In IFN-β deficient mice not only 
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viral-induced IFN-β but also IFN-α production is abolished (Hwang et al., 1995) (Muller et 
al., 1994) (Erlandsson et al., 1998). 
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1.3. Effects of Type I IFNs on the Immune System 
As mentioned above one function of IFNs is to interfere with viral RNA or DNA and viral 
replication. There are two signalling ways how cells combat infections with a pathogen: (1) 
Infected cells produce type I IFN to protect non-infected neighbouring cells. The 
neighbouring cell that responds to IFN is therefore resistant to viral infection. These cells are 
further said to be in an “antiviral state”. (2) Infected cells also combat in an autocrine way by 
inhibiting viral replication in the infected cell. Thus, the IFN system is a huge barrier against 
viral multiplication in the infected host (Abbas K., 2009).  
It has been shown that IFN-α/β have also an immunemodulatory effect on essential effector 
cells in the innate immune system. They are important for the activation of natural killer (NK) 
cells, macrophages and dentritic cells (DCs). The identification of a unique subset of DCs, 
called plasmacytoid DCs that were found to produce huge amounts of IFNα/β, showed that 
IFNs are essential cytokines bridging the innate and adaptive immune systems (Takaoka et 
al., 2006).  
As outlined above, an autocrine positive feedback loop leads to massive synthesis of IFN-α/β 
after viral infection. Several groups have reported that there is evidence for a constitutive 
expression of IFN-α/β under normal physiological conditions, although at a very low level 
(Bocci et al., 1985) (Tovey et al., 1987). The presence of a constitutive low level of IFN was 
detected in mouse embryonic fibroblasts (MEFs), splenocytes and bone marrow cells and was 
described to respond very fast to rapid environmental changes, such as viral infection. It has 
become clear that weak IFN-α/β signaling plays a crucial role in IFN-γ and interleukin (IL)-6 
response. It has also been shown that the constitutive expression of IFN-α/β plays an 
important role in maintaining the tyrosinephosphorylation of the IFNAR receptor chains 
which allows STAT proteins an efficient dimerization upon stimulation with IFN-α/β 
(Takaoka et al., 2000),(Mitani et al., 2001). 
Thus constitutive, weak IFN-α/β signaling renders cells “ready to go” for cellular response 
and therefore also plays a role in the regulation of the adaptive immune response. Figure 4 
demonstrates the hypothetic model of the “ready to go” or also called “revving-up” system 
regulated by low levels of IFN (Taniguchi et al., 2001), (Takaoka et al., 2006). 
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Figure 4. Model of the „revving-up system“ regulated by weak IFN-α/β signaling. Constitutive expression 
of low levels of IFN-α/β enables cells to a fast response upon a viral stimulus. (This figure is taken and modified 
from Takaoka and Yanai, 2006) 
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1.4. Type I IFN and Cancer-Immunosurveillance 
The immune system is not only able to distinguish between self and pathogen or self and non-
self, but between self and transformed self. This concept resulted from studies with 
immunodeficient mice. Immunodeficient Rag2-/- mice, which completely lack natural killer T 
(NKT), T and B cells, developed more spontaneous tumors than their immunocompetent 
counterparts and enforced the hypothesis of cancer-immunosurveillance, which postulates that 
the immune system protects the host against the development of cancer. Cells of the innate 
and the adaptive immune system recognize transformed cells and eliminate them (Smyth et 
al., 2006). 
Further observations that tumors, derived from immunocompetent mice that had to combat an 
intact immune system, have a different immunogenic phenotype than tumors, derived from 
immunodeficient mice, lead to the model of cancer immunoediting (Dunn et al., 2004). Many 
studies in mice and also humans indicated that the immune system can interfere with tumor 
progression, at least in part, by sculpting the immunogenic phenotype of tumors as they 
develop. The model of cancer immunoediting proposes that there are three phases of tumor 
initiation and further progression in a host. The first phase is equivalent with cancer 
immunosurveillance and is called elimination phase. The innate as well as the adaptive 
immune system recognize a transformed cell and eliminate it. But if some cells are not killed 
they proceed to the second or equilibrium phase. In this stage tumor cells remain in the host 
but are not able to disperse due to the immune pressure. But when tumor cells overcome the 
immune system they can proliferate which finally leads to tumor progression. Because tumor 
cells could escape the immune system, the third phase is called escape phase (Figure. 5) 
(Dunn et al., 2004). 
It has been shown recently that IFNs have a critical role in the elimination phase of cancer 
immunoediting. Both, type I IFNs and IFNγ, play important roles in promoting host antitumor 
immunity. It has been reported that neutralization of IFN-α/β with polyclonal antiserum 
enhances the growth of transplanted, syngeneic (genetically identical and immunologically 
compatible) tumors (Gresser et al., 1983). Dunn and colleagues used models for tumor 
transplantation and primary tumor formation to show the critical function of endogenously 
produced IFN-α/β in cancer immunoediting. They found that endogenously produced IFN-
α/β is required for rejection of highly immunogenic MCA sarcomas (MCA= 
methylcholantrene, a chemical carcinogen that induces sarcomas after subcutaneous 
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injection). Interestingly, IFNs do not mediate their antitumor activity on tumor cells but on 
hematopoietic cells of the host (Dunn et al., 2005).  
 
Figure. 5. Model of cancer immunoediting. There are 3 phases involved in cancer immunoediting: the first 
phase is called elimination phase. Transformed cells are recognized and killed by the innate and adaptive 
immune system. Cells that survive enter the equilibrium phase where they persist but cannot proliferate due to 
immune pressure. The third phase is called escape phase and starts when tumor cells overcome the immune 
system. (This figure is taken and modified from (Dunn et al., 2006)). 
Besides their important role in cancer immunosurveillance type I IFNs might play also an 
antitumorgenic role in the process of cell transformation. Type I IFNs were found to up-
regulate the expression of the tumor suppressor protein p53 and IFN-β was reported to inhibit 
the in vitro transformation of wt mouse embryonic fibriblasts (MEFs) (Takaoka et al., 2003). 
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1.5. Effects of Type I IFNs on Natural Killer (Nk) Cells 
As outlined above, there is broad evidence that type I IFNs are essential in bridging the innate 
and the adaptive immune system. Interestingly, they do not only act on immune cells but also 
interfere with tumor cells. Type I IFNs have been found to inhibit the proliferation of tumor 
cells and to support the immune response by enhancing the cytolytic activity of Nk cells 
(Gutterman, 1994, Kirkwood, 2002).  
Nk cells are part of the innate immune system and recognize infected, transformed or stressed 
cells. They are present mainly in blood and the spleen and are rare in other lymphoid organs.  
Nk cells have several activating and inhibiting cell surface receptors. The balance between 
activating and inhibiting signals regulates Nk cell activation. Inhibitory receptors bind to the 
major histocompatibility complex (MHC) class I molecules. Activating receptors bind various 
activating ligands expressed on target cells. Tumor cells often downregulate MHC class I 
expression to escape cytotoxic T lymphocytes (CTLs). However, downregulation of MHC 
class I on a target cell leads to its recognition by the Nk cell (Abbas K., 2009).  
Type I IFN signaling has been shown to play a critical role in Nk cell regulation. Swann and 
his colleagues again used IFNAR deficient mice to demonstrate the essential role of type I 
IFNs in the regulation of Nk cell numbers, activation and antitumor activity. They could show 
that Nk cell numbers were diminished and the Nk cell mediated tumor response was 
decreased in IFNAR deficient mice (Swann et al., 2007). As mentioned above, constitutive 
expression of low levels of IFN-α/β might be a source of IFN for maintaining the Nk cell 
population. Overall, further studies are required to elucidate the mechanism how type I IFNs 
influence Nk cell homeostasis.  
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1.6. Type I IFNs and Angiogenesis 
Normal organ growth and development relies on blood supply that depends on endothelial 
cells, which form vascular walls. A new blood capillary forms by sprouting of an endothelial 
cell from the wall of an existing small vessel. This process is called angiogenesis and the role 
of angiogenesis in human tumor progression was originally postulated by Judah Folkman in 
1971 (Folkman, 1971). Furthermore it has been recognized that inhibition of angiogenesis 
could be a useful means of solid tumor therapy. It has also been shown that angiogenesis 
might be involved in hematological malignancies, such as acute lymphoblastic and myeloid 
leukemias (ALL and AML) (Bauvois et al., 2002) or B-chronic lymphocytic leukemia (B-
CLL) (Kini et al., 2000). Since the important role of the vascular endothelial growth factor 
(VEGF) in angiogenesis has been realized, there are also studies that demonstrate that VEGF 
triggers growth, survival and progression of leukemic cells. These observations suggest that 
angiogenesis is not only crucial in solid tumor formation but also in the pathogenesis of 
hematologic malignancies and metastatic spread through the lymphatic vasculature (Podar et 
al., 2005) as illustrated in Figure 6.  
Figure 6. Schematic overview of lymphangiogenesis involved in tumor formation and metastastatic 
spread. Tumor cells secrete VEGF that binds to corresponding VEGF receptors on lymphatic vessels, 
which leads to the formation of new vessels that support tumor growth and spreading of tumor cells. 
(This picture was taken and modified from (Achen, 2005). 
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During the last several years a number of molecular tools helped to identify different pro-
angiogenic and anti-angiogenic factors that either stimulate or inhibit proliferation of 
endothelial cells. The shift in balance between the production of anti-angiogenic and pro-
angiogenic factors is called an angiogenic switch and is crucial in promoting tumor growth 
(Hanahan et al., 1996). O’Reilly and his team discovered the inhibitors of angiogenesis 
angiostatin and endostatin. Injection of these inhibitors into mice showed that solid tumor 
growth and formation of metastasis was suppressed (O'Reilly et al., 1994b, O'Reilly et al., 
1994a, O'Reilly et al., 1997).  
Even though little is known about type I IFNs and its impact on leukemia it is published that 
tumor cells treated with IFN-α/β in vitro and in the mouse model system in vivo were 
significantly less competent to initiate angiogenesis. This effect results from the anti-
proliferative function of type I IFNs (fewer tumor cells initiate less angiogenesis) and they are 
supposed to inhibit the production and release of pro-angiogenic factors from the tumor cell 
or lymphocytes (Sidky et al., 1987). Other studies have demonstrated the anti-angiogenic 
function of type I IFNs by inhibiting the production of the angiogenic growth factor basic 
fibroblast growth factor (bFGF) (Singh et al., 1995), vascular endothelial growth factor 
(VEGF) (Rosewicz et al., 2004) and interleukin-8 (IL-8) in human melanoma cells (Singh et 
al., 1996). Type I IFNs inhibit angiogenesis by preventing endothelial cell differentiation. 
IFN-β treated endothelial cells are able to form new, small vessels but fail to form a complex 
capillary-like network (Taylor et al., 2008). Furthermore matrix metalloproteinase-9 (MMP-
9) has been identified as an important factor in angiogenesis. MMP-9 is capable of degrading 
type IV and V collagens, laminin and fibronectin, which are major components of the 
extracellular matrix (ECM). Proteolytic degradation of the ECM is also an important step in 
angiogenesis. A study on B-CLL patient samples revealed that type I IFNs suppress the 
production of MMP-9, indicating the importance of type I IFNs in inhibiting tumor 
angiogenesis (Bauvois et al., 2002). Furthermore it has been reported that human bcr-abl+ 
cells, derived from CML patients, as well as murine cells, transfected with the p185, p210 and 
p230 BCR-ABL tyrosine kinase versions, secrete angiogenic factors (VEGF, IL-8, HGF and 
FGF-2) and MMPs (MMP-9 and MMP-2) (Janowska-Wieczorek et al., 2002). Moreover, 
leukemic cells express the pro-angiogenic factor VEGF as well as the VEGF receptor, which 
results in the generation of an autocrine loop that supports the proliferation and survival of 
leukemic cells (Kay et al., 2002, Dias et al., 2000, Wegiel et al., 2009).  
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1.7. Abelson Induced Leukemia 
The ABL family of proteins encodes tightly regulated non-receptor tyrosine kinases. One 
member is the ABL protein. Usually the cellular ABL tyrosine kinase (c-ABL) activity is 
tightly regulated and cannot transform fibroblasts and hematopoietic cells, even when it is 
over-expressed (Kruh et al., 1986, Wang et al., 1984). The c-ABL protein can be localized in 
the nucleus and in the cytoplasm. It has been postulated that c-ABL serves as cell growth 
promoter as well as cell growth inhibitor, depending on various circumstances. Van Etten and 
co-workers have shown that c-ABL on one hand stimulates the transcription of S-phase genes, 
while on the other hand c-ABL has been described to inhibit cell growth in the G1 phase of 
the cell cycle. There is also evidence that c-ABL modulates cell response to genotoxic stress 
as well as it influences the cytoskeleton and neuronal development (Van Etten, 1999). 
Abl-deficient mice are variably affected. They are smaller, with abnormal head and eye 
development and often die perinatal (Ren, 2005). Mutations in the abl gene lead to a 
constitutively active ABL tyrosine kinase that is mostly cytosolic and always associated with 
transformation (Rosenberg et al., 1988). ABL oncoproteins include v-abl (which is 
retrovirally transduced) and the translocation products BCR-ABL and TEL-ABL. Those 
oncoproteins are known to activate several different signaling pathways constitutively, 
including Ras, Myc, PI3-kinase and the JAK-STAT pathway (Danial et al., 2000).  
In our study we used the replication incompetent mouse pathogenic Abelson retrovirus, which 
is reported to induce a slowly progressing murine leukemia with lymphoblastic infiltrations of 
the lymph nodes, bone marrow and spleen (Rabstein et al., 1971).  
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1.7.1. The BCR-ABL Fusion 
The generation of a BCR-ABL fusion protein leads to malignant outcomes in humans. Acute 
lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) are the consequences of 
reciprocal or balanced translocation between the 5’ fragment of the bcr gene, located on 
chromosome 22 and the 3’ portion of the abl gene, located on chromosome 9. This 
translocation leads to a shortend chromosome 22, which results in the so-called Philadelphia 
chromosome (Nowell et al., 1960) shown in Figure 7. The bcr-abl fusion gene encodes a 
constitutively active tyrosine kinase that is involved in different signaling pathways as 
mentioned above. 
  
Figure 7. Overview of the occurring reciprocal translocation of chromosome 9 and chromosome 22. The 
translocation of the abl gene, located at 9q34, and the bcr gene, located at 22q11, yields in the formation of the 
Philadelphia chromosome (Ph22q-). The translocation 9q+ has no known phenotype. (This picture was taken and 
modified from http://a0.vox.com/6a00d10a7a748d8bfa00e398a3cdf80001-500pi) 
The structures of the ABL tyrosine kinase and the BCR signaling protein have been studied 
extensively. It is known that there are two isoforms of ABL (human type 1a and 1b), which 
result from alternative splicing of Exon 1. As shown in Figure 8 isoform 1b has a 
myristoylation modification that can attach the ABL protein to a membrane protein. 
Futhermore, ABL contains tandem SRC homology 3 (SH3), SH2 and the tyrosine kinase 
domain. At the C-terminal end there are four prolin-rich SH3 binding sites (PPs), three 
nuclear localizations signals (NLS), one nuclear export signal (NES), a DNA binding domain 
(DBD) and an actin-binding domain located. The BCR protein contains a coiled-coiled (cc) 
oligomerization domain, a serine/theronin (S/T) kinase domain, a Dbl/CDC24 guanine-
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nucleotide exchange factor homology (DH) domain, a calcium-dependent lipid binding site, a 
RAC guanosine triphosphate-activating protein (RAC-GAP), a binding site for growth-factor 
receptor bound protein 2 (GRB2) as well as for GRB10 and the ABL proteins. Different 
forms of the BCR-ABL protein with different molecular weight can be generated: p185 BCR-
ABL, p210 BCR-ABL and p230 BCR-ABL. The three proteins are associated with ALL, 
CML and a milder form of CML (Ren, 2005).  
 
Figure 8. Structure of the ABL and BCR protein. ABL: The blue border indicates the fusion region with the 
bcr gene.  Myr, myristoyl modification; SH3 and SH2 domain; tyrosine kinase domain; PP, proline rich SH3-
binding domain; NLS, nuclear localization signal; DBD, DNA-binding domain; ABD, actin-binding domain; 
NES, nuclear export signal. BCR: Red borders indicate the different regions on the chromosome that can fuse 
with the abl gene, yielding in different BCR-ABL proteins. cc, coiled-coiled domain; S/T kinase, serine/threonin 
kinase; DH, Dbl/CDC24 guanine-nucleotide exchange factor homology; PH, pleckstrin homology domain; 
CaLB, calcium-dependent lipid binding site; RAC-GAP, RAC guanosine triphosphate-activating protein. This 
figure is modified and taken from (Ren, 2005). 
As demonstrated in Figure 9 BCR-ABL proteins can form dimers or tetramers by binding of 
their cc domains and further trans-phosphorylate two tyrosine residues. Trans-
phosphorylation initiates downstream leukemogenic signaling (Ren, 2005).  
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Figure 9. Structure of the BCR/ABL p210 fusion protein. BCR/ABL proteins form dimers or tetramers by 
interaction of their cc domains, followed by trans-autophosphorylation of two tyrosine residues indicated in the 
red border. Autophosphorylation leads to a constitutively activated tyrosine kinase function of the BCR/ABL 
fusion protein and triggers downstream signaling. Blue arrows indicate the fusion point of the bcr gene and the 
abl gene. This Figure was modified and taken from (Ren, 2005). 
The expression of the BCR-ABL tyrosine kinase in self-renewing, hematopoietic stem cells is 
responsible for the onset of CML. CML progresses through 3 phases starting with an initial 
chronic phase. The chronic phase has a median duration of 3-4 years. In this phase there are 
fewer then 5% blasts in the blood and bone marrow but the expansion of the granulocytic cell 
type is characteristic. Most cases of CML are diagnosed at this phase and patients in the 
chronic phase of CML have a good prognosis after therapeutic actions. In the following 
accelerated phase the number of blasts increases up to 15% and this phase can last weeks to 
month. Often an additional abnormality leads to the onset of the third phase of CML, called 
the acute blastic phase or blast crisis that is comparable to the clinical pattern of ALL and in 
which more than 30% of cells are blasts. At this point, CML has become an aggressive fast 
growing leukemia, which results in a poor prognosis for patients.  
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1.7.2. The Abelson virus (A-MuLV) 
In 1070 Abelson and Rabstein observed in an infection experiment with Moloney murine 
leukemia virus (Mo-MuLV), a virus with well-characterized thymus tropism (Moloney, 
1960), one mouse that developed an unusual lymphosarcoma. Thereby they isolated an acute 
transforming retrovirus, named Abelson Murine Leukemia Virus (A-MuLV) that was capable 
of inducing multiple tumors of the lymph nodes with bone marrow infiltrations in the mouse 
(Abelson et al., 1970, Rabstein et al., 1971). Further studies demonstrated that the virus was 
able to transform fibroblasts (Scher et al., 1975) and also cells derived from lymphoid tissues 
with 10-100-fold greater efficiency in vitro (Rosenberg et al., 1975).  
Studies concerning the molecular structure of A-MuLV revealed that it originates from the 
recombination of the Mo-MuLV with the murine c-abl gene generating a fusion gene 
containing Mo-MuLV gag and a truncated version of the endogenous murine c-abl gene that 
was named v-abl (Shore et al., 2002). Figure 10 demonstrates a schematic overview of the 
viral transduction event.  
 
 
Figure 10. Schematic diagram of the integration of the Mo-MuLV gag into the murine c-abl gene. The 
replication competent murine leukemia virus Mo-MuLV integrates into Exon 3 of the endogenous murine c-abl 
gene yielding in the replication incompetent A-MuLV encoding v-abl. This picture was taken from (Shore et al., 
2002). 
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It has been shown that the size of the v-abl gene product can range between 90-160 kDa. 
p120v-Abl and p160v-Abl have been studied extensively and have been identified as plasma 
membrane-associated non-receptor tyrosine kinases. p120v-Abl was shown to phosphorylate 
itself as well as tyrosine residues of exogenous substrates. Infection of hematopoietic cells 
results in the abrogation of cytokine-dependent growth and the disability to differentiate in 
response to cytokines. (Shore et al., 2002). 
As mentioned above in vitro A-MuLV transfects pre-B cells and fibroblasts, whereas in vivo 
pro-B cells are the major target of A-MuLV (Witte, 1986). After transfection, pro-B cells are 
not able to differentiate, which results in the accumulation of immature B cells, which are 
characterized by B220, CD19 and CD43 cell surface markers, and further the development of 
B-lymphoid leukemia in mice.  
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1.8. Aim of this Master Thesis 
The reciprocal translocation between the abl gene on chromosome 9 and the bcr gene on 
chromosome 22 yields a bcr-abl fusion gene that expresses a constitutive active tyrosine 
kinase. One of the activated pathways downstream of BCR-ABL is the JAK/STAT pathway, 
which is also activated by type I IFNs.  
As outlined in the introduction, IFNs do not only play a crucial role in the defence against 
viral infections but were also shown to have a critical role in the elimination phase of cancer 
immunoediting. Several studies have demonstrated the importance of type I IFNs in 
promoting host anti-tumor immunity. The possible antitumor activity of type I IFNs in v-abl 
induced B-lymphoid leukemia has been investigated previously in our lab. In these studies, 
mice deficient for type I IFN signaling, namely IFNAR1-/- and IFN-β-/- mice, were used. 
IFNAR1-/- and IFN-β-/- bone marrow cell lines were retrovirally transformed with the v-abl 
oncogene and displayed no significant differences in proliferation and apoptosis in vitro. 
When newborn mice were infected with the Abelson virus IFNAR1 as well as IFN-β deficient 
mice succumbed to B-lymphoid leukemia significantly faster than their wt controls. 
Furthermore bone marrow transplantation of v-abl transformed cell lines into 
immuncompromised Rag2-/- mice revealed that lack of IFNAR1 and IFN-β significantly 
increased leukemia formation (Neugebauer, 2007).  
The aim of this study was to clarify whether these previous observations are caused by tumor 
cell intrinsic (cell-autonomous) properties or by a defect in the immune system. Therefore, 
IFNARfl/flCD19cre+ mice were used to delete the IFNAR1 chain of the type I IFN receptor 
specifically in B-lymphocytes. We performed newborn infections with IFNARfl/flCD19cre+ 
mice and their wildtype littermates to test whether the lack of type I IFN signaling in B cells 
would lead to faster progression of B-lymphoid leukemia.  
Furthermore, we wanted to investigate the basal level of IFN-β in v-abl transformed tumor 
cells. A constitutive low level of type I IFN has been detected in mouse embryonic fibroblasts 
(MEFs), splenocytes and bone marrow cells that enables cells to a very fast response to rapid 
environmental changes, such as viral infection. We therefore addressed the question whether 
v-abl transformed wt tumor cells might also produce a low level of IFN-β that inhibits 
leukemia progression and leads to the above-mentioned phenotype in transplantation 
experiments with Rag2-/- mice. 
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Another aim of this master thesis was to study the effect of type I IFNs on angiogenesis. We 
injected Rag2-/-γc-/- mice, which lack functional Nk, T and B cells, subcutaneously and 
looked for vascularisation. Rag2-/-γc-/- mice are particularly suited for injection experiments 
because cell autonomous properties are not affected by a functional immune system. 
Furthermore we analysed v-abl transformed cell lines for differences in expression levels of 
genes important in angiogenesis. Thus we hoped to identify genes affected by type I IFN 
signaling and to investigate the mechanism underlying the inhibitory function of type I IFNs 
in angiogenesis.  
Experimental Procedures 
23 
2. Experimental Procedures 
2.1. Cell Culture 
2.1.1. Culture conditions 
All cell lines were kept at humidified 37°C and 5% CO2. V-abl transformed cell lines were 
maintained in RPMI-1640 medium (PAA Laboratories) containing 10% heat inactivated FCS 
(PAA Laboratories), 100 U/ml penicillin/streptomycin (PAA Laboratories) and 5 µM beta-
mercaptoethanol (Sigma). Raw cells were cultured in DMEM High Glucose (4.5g/l) medium 
(PAA Laboratories) containing 10% heat inactivated FCS (PAA Laboratories) and 100 U/ml 
penicillin/streptomycin (PAA Laboratories). For splitting RAW dissociation buffer (1.35 M 
KCl, 0.15 M sodium citrate, sterile H2O) was used. 54C12 producer cells were cultured in 
DMEM High Glucose (4.5g/l) medium (PAA Laboratories) containing 10% heat inactivated 
FCS, 100 U/ml penicillin/streptomycin (PAA Laboratories) and 5 µM beta-mercaptoethanol 
(Sigma). Endothelial cells were cultured in RPMI-1640 medium (PAA Laboratories) 
containing 10% heat inactivated FCS (PAA Laboratories), 100 U/ml penicillin/streptomycin 
(PAA Laboratories) and 5 µM beta-mercaptoethanol (Sigma) mixed 1:1 with Epithelial Cell 
Growth Medium MV (PromoCell). For splitting Trypsin-EDTA (1x) (PAA Laboratories) was 
used.   
For storage at -80 °C the stable cell lines were kept in 90% heat inactivated FCS (PAA 
Laboratories) enriched with 10% DMSO (Fluka).  
2.1.2. Production of Abelson leukemia virus 
For production of the ecotropic replication-deficient form of the Abelson retrovirus (A-
MuLV), which encodes the v-abl oncogene, 54C12 cells were cultured on 10 cm cell culture 
dishes. Cells were grown in complete DMEM High Glucose medium until grown to 100 % 
confluency. Cells were centrifuged at 1200 rpm for 5 minutes and sowed in complete RPMI-
1460 medium for one day. Supernatant was collected, centrifuged at 1200 rpm for 5 minutes 
and filtered sterilely through a 0.45 µM syringe filter (Abdool et al.). Viral supernatant was 
subsequently shock frozen in liquid nitrogen and stored at -80°C. 
Experimental Procedures 
24 
2.1.3. Stimulation of RAW 264.7 cells 
For stimulation of RAW 264.7 cells with Lipopolisaccharid (LPS) (Sigma), cells were grown 
in 10 cm culture dishes until 90-100% confluency and stimulated with 100 ng/ml of LPS for 
one hour at 37°C/ 5% CO2. Afterwards cells were harvested, centrifuged for 5 minutes at 
1000 rpm and washed with phosphate buffered saline (PBS).  
2.1.4. Scratch assay 
1x105 endothelial cells were sowed on a 6-well culture dish in complete RPMI medium. After 
24 hours medium was removed and a scratch through the well was performed with a yellow 
tip. Afterwards cells were washed carefully 2 times with PBS and covered with 2 ml of 
different supernatants. 
For supernatant production 1x106 v-abl transformed cells of different genotypes were sowed 
in complete RPMI medium on a 10 cm culture dish and collected after 24 hours by 
centrifugation at 1400 rpm for 4 minutes. Afterwards supernatant was filtered sterilely 
through a 0.45 µM syringe filter.  
For identification of proliferation properties of endothelial cells grown in different 
supernatants pictures of cells were taken under a microscope (Nikon, Eclipse TS100; 10 times 
magnified) using a digital camera (Nikon, Coolpix P5000; Zoom F2.7) at time point 0h and 
time point 24h. To analyze proliferation differences a program (tScratch) was used that 
measures, compares and evaluates statistically open areas on culture dishes. 
2.2. Flow cytrometric analysis (FACS) 
For flow cytometry 50 µL of cell suspensions (~106 cells/ml)  were incubated with 50 µL 
PBS, Fc-block and the B cell specific antibodies (listed in tab. X) on ice in the dark for 20 
minutes.  Cells were washed with PBS, centrifuged for 4 minutes at 1200 rpm and analyzed in 
a FACS CantoTM II (Becton Dickinson) with BD FACSDiva software. 
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Antibodies used for flow cytometry: 
B cell staining BM Name Dilution Source 
  Fc-block 1:100 BD Pharmingen 
  APC Cy7-conjugated CD19 1:50 BD Pharmingen 
  
PerCP-Cy5.5-conjugated 
B220 
1:100 BD Pharmingen 
 PE conjugated CD43 1:50 BD Pharmingen 
 PE-Cy7 conjugated NK1.1 1:100 BD Pharmingen 
  APC conjugated DX5 1:100 BD Pharmingen 
Table 1. Antibodies used for flow cytometry. 
2.3. DNA Methods 
2.3.1. DNA isolation 
For DNA isolation mouse tail tips were incubated in 500 µL tail prep buffer [50 mM Tris HCl 
pH=8,0, 100 mM NA2EDTA, 100 mM NaCl, 1%SDS] and 12,5 µL proteinase K (0,5 mg/mL) 
either over night for 55 °C or for 2 hours at 55 °C 650 rpm shaking. 
For protein precipitation 200 µL 5 M NaCl were added. After inverting the tubes they were 
centrifuged at 4 °C for15 minutes at 13600rpm. 
450 µL of the supernatant were transferred to a new eppendorf tube and DNA was 
precipitated by adding 300 µL 2-propanol. Tubes were inverted and incubated at -20 °C for at 
least 5 minutes. Afterwards they were centrifuged again at 4 °C for 15 minutes at 13600 rpm. 
DNA pellets were washed with 1 mL 70% Ethanol at 4 °C for 10 minutes/13600 rpm. The 
supernatant was removed, the pellets were left to dry and dissolved in 150 µl H2O for at least 
2 hours shaking at 37 °C. 
2.3.2. Reverse-transcriptase polymerase chain reaction (RT-PCR) 
For definite genotyping of mice polymerase chain reaction was performed. Identification of 
the IFNAR floxed (fl) allele and the wt allele requires two different primer pairs but the 
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reactions can be performed at the same PCR program.  For identification of the CD19 cre 
recombinase allele and the IFNAR fl/wt allele each reaction includes 20.5 µl H2O, 2.5 µl 10x 
DreamTaq buffer (Fermentas), 0.25 µl dNTPs (10mM), 0.25 µl forward primer (10µM), 
0.25µl reverse primer (10µM) and 0.25 µl DreamTaq DNA polymerase (Fermentas).  
Gene Primer sequence PCR [ no.(°C/s)] 
Product 
size 
IFNAR fl/fl 
5´-CAGGCCACTCTGCATTTCCTC-3´(F) 
5´-CTTTTTGGATCGATCCATAACTTCG-3´(R) 
358 bp 
IFNAR wt 
5´-CAGGCCACTCTGCATTTCCTC-3´(F) 
5´-CTTTTTGGATATCAAGAAAGCAAAT-3´(R) 
4´94°C-40x[30´´94°C-
30´´58°C-1´72°C]-
10´72°C-4°C ] 
358 bp 
IFNAR Δ 
5´-GGTTAAGCTCCTTGCTGCTATCTGG-3´(F) 
5´-TTGGAGATGCAATCTGCTACTCAGC-3´(R) 
4´94°C-40x[30´´94°C-
30´´59°C-1´72°C]-
10´72°C-4°C ] 
Δ 339 bp 
fl/fl 1160 
bp 
CRE 
5´-CGGTCGATGCAACGAGTGATGAGG-3´(F) 
5´-CCAGAGACGGAAATCCATCGCTCG-3´(R) 
4´94°C-40x[30´´94°C-
30´´55°C-1´30´´72°C]-
10´72°C-4°C 
500 bp 
Table 2. Primer sequences used for genotyping of mice. 
2.3.3. Electrophoresis 
Agarose gel electrophoresis was performed in 1x TAE buffer (40mM Tris-acetat, 1mM 
NaEDTA (pH=8.3)) as running and preparation buffer. For visualization of DNA under UV 
light 6 µl of ethidiumbromid were added to 100 ml of 1.5%-2% agarose in 1x TAE.  Samples 
were mixed with 5x Orange G loading dye and gels were run at 120V. GeneRuler 100bp 
DNA Ladder (Fermentas, #SM0241) was used as DNA marker.  
2.3.4. RNA isolation 
Total RNA was isolated from v-abl transformed cells using TRIzol reagent (Sigma). Cells 
were harvested from the culture dish and centrifuged for 5 minutes at 1000 rpm.  Cell pellets 
were homogenized in 1 ml of TRI reagent and centrifuged for 10 minutes at 12000g at 4 °C.  
The supernatant was transferred into a new tube. After 5 minutes at room temperature 0.2 ml 
of chloroform were added and tubes were shaken vigorously. Supernatants were left to stand 
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for 15 minutes and centrifuged for 15 minutes at 12000g at 4 °C. The aqueous phase was 
transferred into a new tube and mixed with 0.5 ml of isopropanol. After 15 minutes at room 
temperature samples were centrifuged for 10 minutes at 12000g at 4 °C.  The supernatant was 
discarded and RNA pellets were washed with 1 ml of 75% ethanol. Samples were centrifuged 
for 5 minutes at 12000 g at 4 °C. Afterwards the supernatant was removed and RNA pellets 
were left to air-dry for 10 minutes. RNA pellets were resuspended in 30 µl of RNAse free 
water (Fluka). Samples were shaken at 55 °C for 15 minutes.  
2.3.5. DNA digest 
For DNA digest RNA samples were incubated with 14.5 µl RNAse free water, 0.5 µl DNAse 
I recombinant, RNAse-free (Roche) and 5 µl 10x incubation buffer (Roche) for 20 minutes at 
room temperature. To stop the reaction 0.2 µl of 0.2 M EDTA (pH=8) were added and 
samples were incubated for 10 minutes at 75 °C. Finally RNA samples were stored at -80 °C. 
2.3.6. Reverse transcriptase reaction 
Total RNA was converted into cDNA using the Gene Amp RNA PCR Core Kit (Applied 
Biosystems).  3 µg RNA were mixed with MgCl2 solution (25mM), 10x PCR Buffer II, dATP 
(10mM), dTTP (10mM), dGTP (10mM), dCTP (10mM), Oligo d(T)16 (50 µM), RNAse 
Inhibitor (20U/µl), MuLV Reverse Transcriptase (50U/µl) and an appropriate volume of 
RNAse free water and after 10 minutes at room temperature samples were incubated at 42 °C 
for 60 minutes that followed 5 minutes at 99 °C. Samples were centrifuged and 30 µl of 
RNAse free water was added. 
cDNA concentration  was measured with a BioPhotometer 6131 (eppendorf). cDNA samples 
were stored at -20 °C. 
2.3.7. Quantitative real-time PCR (qRT-PCR) 
For measuring the relative genexpression quantitative real-time PCR (qRT-PCR) was 
performed. For the relative expression of IFNβ and VEGF different primer pairs were used 
but the reactions were performed at the same PCR program. Each reaction includes 13.6 µl 
H2O, 2.5 µl 10x buffer advanced with Mg2+ (5 Prime), 2.25 µl DMSO, 0.5 µl dNTPs (10mM), 
Sybr green (diluted 1:100 in DMSO) and 0.1 µl Taq DNA polymerase (5 Prime). The SYBR 
green method was applied for determining concentrations of double stranded PCR products 
obtained after PCR using intron-spanning primers. The PCR cycle in which a given mRNA 
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specific fluorescent signal crossed an arbitrary threshold was defined as CT.cycle. The 
difference of a gene-specific CT value to that of an endogenous housekeeping gene (GAPDH) 
was called DCT value. Individual DCT for all genotypes were calculated and compared 
relatively to controls. The primer sequences were designed manually. The DNA sequences of 
primers used for qRT-PCR analysis are given in Table 3.  
Each qRT-PCR was performed in triplicates. 
Gene Primer sequence PCR [no.(°C/s)] Product size 
GAPDH 
5´-AGAAGGTGGTGAAGCAGGCATC-3´ (Fw) 
5´-CGGCATCGAAGGTGGAAGAGTG-3´(Rv) 
100bp 
IFNβ 
5´-CACTGCAGCCTTTGACAGCCTTTG-3´(Fw) 
5´-CCATAGGGATCTTGAAGTCCGC-3´(Rv) 
251bp 
VEGF 
5´-GCACAGCAGATGTGAATGCAG-3´(Fw) 
5´-CGCTCTGAACAAGGCTCACA-3´(Rv) 
1´94 °C- 40x[1´94 
°C-30´´55 °C-30´´72 
°C]-15´´95 °C-
15´´60 °C-15´´95 °C 
73bp 
Table 3. Primer sequences used for quantitative qRT-PCR. 
2.3.8. Oligo GEArray Expression analysis for angiogenesis 
For determination of expression and regulation of genes involved in angiogenesis an Oligo 
GEArray® System (SABiosciences) including an Oligo GEArray Reagent Kit was performed 
according to the user manual. 1 µg of isolated total RNA was transcribed into cRNA labeled 
with Biotin-16-UTP (Roche) using the TrueLabeling-AMPTM 2.0 kit. 3 µg of biotin-labeled 
cRNA were hybridized over night at 60 °C with the pre-hybridized array membrane. Next day 
the array membrane was washed several times with wash solution 1 (2x SSC, 1% SDS) and 
was solution 2 (0.1x SSC, 0.5% SDS) at 60 °C. Cooled array membranes were further 
blocked with GEAblocking Solution Q, washed with 1x Buffer F and Buffer G, respectively. 
RNA detection was achieved using CDP-Star chemiluminescent substrate on photosensitive 
films. GEArray Expression Analysis Suite 2.0 was used for analysis of the array membranes. 
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2.4. Protein analysis 
2.4.1. Cell lysates  
Cell pellets either from cultured cell lines or tumor samples were homogenized in an 
appropriate (400-600 µl) volume of Carin Lysis Buffer (20mM Tris-Base (pH= 8.0), 138 mM 
NaCl, 10 mM EDTA, 100 mM natriumfluorid, 1% NP40, 10% glycerol, 4 mM 
natriumorthovanadate (freshly added), 10 µl Complete Mini EDTA free Protease Inhibitor 
Cocktail ® as indicated by the manufacturer (Roche)), shock frozen in liquid nitrogen and 
stored at -80 °C. 
2.4.2. Protein concentration 
For the measurement of the protein concentration samples were unfrozen and centrifuged for 
5 minutes at 13 600 rpm. Supernatant was used for protein measurement with BCA Protein 
Assay Reagent (Pierce Biotechnology) and immediately shock frozen in liquid nitrogen and 
stored at -80 °C.  1 ml Reagent A and 20 µl Reagent B of the BCA kit were mixed with the 
protein supernatant and incubated for 40 minutes at 36 °C.  Protein concentration was 
measured at 562nm. 
2.4.3. Electrophoresis 
Protein samples were separated on 10% polyacrylamid gels in 1xSDS-PAGE running buffer 
(25 mM Tris-base, 192 mM glycine and 0.1% sodium dodecyl sulphate (SDS)) at 140V 
constant current per 0.75 mm mini-gel (Biorad). Supernatants were mixed with 4x laemmli 
buffer (250 mM Tris-base (pH=6.8), 8% SDS, 20% beta-mercaptoethanol, 43.4% glycerol), 
heated for 5 minutes at 95°C, centrifuged and well mixed before loading. As marker, 
PageRuler prestained protein ladder (#SM 0671, Fermentas) was used. 
2.4.4. Western blotting 
Proteins were blotted onto a nitrocellulose transfer membrane (PROTRAN®, Whatman®) at 
0.4 A for 40 minutes (Transblot SD®; Biorad) per 0.75 mm mini-gel using electrotransfer 
buffer (25 mM Tris-base, 192 mM Glycin). All nitrocellulose membranes were blocked with 
5% milk/ Tris-buffered saline with 0.1% Tween (TBS-T) (200 mM Tris-base, 1500 mM 
NaCl, pH=7.5) for 1 hour at room temperature. First antibodies were incubated in 3% 
BSA/TBS-T over night at 4 °C and second antibodies were incubated in 1% BSA/TBS-T for 
1 hour at room temperature. Membranes were washed with TBS-T supplemented with 0.1% 
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SDS for 1 hour between the incubation steps. Protein detection was achieved by ECLTM 
(enhanced chemiluminiscence detection; Amersham Biosiences/GE Healthcare) on 
photosensitive films. 
2.5. Histology 
Spleens of diseased mice were fixed with 4% formaldehyde for 48 hours. Afterwards they 
were washed in PBS and embedded in paraffin. 5µm thick sections were cut and stained with 
Hematoxylin and Eosin (H&E) or with Periodic acid solution and Schiff reagent (PAS). 
Confocal images were taken using a Zeiss Axio Imager Z1 microscope. 
2.6. Mice 
2.6.1. Mouse strains 
All mice were maintained at the Medical University of Vienna and the University of 
Veterinary Medicine of Vienna. Due to the compromised immune status of the knock out 
mice strains, they were maintained under pathogen free conditions in Micro-isolator TM cages. 
Cages, food and water were sterilized and the mice were handled in laminar flow. The 
offspring was weaned at three weeks of age and for individual identification one ear of the 
animal was tagged. Tail-tip biopsy was performed for genotyping of the mice. 
All mouse strains, which served as experimental model systems were on the C57BL/6 mouse 
background. Furthermore only littermates of the mouse strains were compared for 
experimental purpose among each other. All mouse experiments were carried out in 
accordance with protocols approved with the Austrian law. 
For this study, the IFNARfl/fl mouse strain was obtained from Ulrich Kalinke. IFNARfl/fl mice 
were originally crossed with c-junfl/fl, CD19 cre + mice and Nk cre+ mice and its following 
offspring to breed IFNARfl/flCD19cre + mice and IFNARfl/flNk cre+ mice. For further 
experiments IFNARfl/flCD19 cre+ / Nkcre+ and IFNARfl/flCD19 cre- / Nk cre- littermate 
controls were analysed.  
Additionally, following mouse strains served as experimental model systems: 
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2.6.2. Rag2-/-γc -/- mice 
In this study Rag2-/-γc -/- mice, which lack functional B-, T- and Nk-cells served as a 
leukemia mouse model system (Mazurier et al., 1999). 
2.6.3. Injection of Abelson retrovirus (A-MuLV) into newborn mice 
For newborn infection experiments, newborn mice were injected intraperitoneally and into the 
nuchal fold with 100 µl of replication incompetent ecotropic retrovirus (A-MuLV) encoding 
for v-abl. Mice were checked daily for disease onset. Diseased mice were sacrificed by 
cervical dislocation and blood samples were taken for blood smears, FACS analysis and 
cultivation of the cells. Spleens and lymph nodes were excised and analysed for their weight, 
FACS analysis and cultivation of the cells. For further histological analysis pathological 
sections of the spleen, liver and lymph nodes were taken and kept in 4% formaldehyde 
(Sigma) for 2 days and afterwards stored in PBS at 4°C. 
The other part of the excised spleens and lymph nodes were pushed through a 70 µm cell-
strainer (Abdool et al.) to obtain a single cell suspension. Subsequently bone marrow cells 
were isolated from femur and tibiae by flushing them with syringes.  All cells suspensions 
were centrifuged for 5 minutes at 1 000 rpm. Supernatants were aspired and splenocytes were 
resuspended in erythrocyte lysis buffer (0.4 M NH4Cl, 10 mM KHCO3, 0.1 mM NaEDTA) to 
get rid of red blood cells. After 5-10 minutes centrifugation cells were centrifuged as before, 
supernatant aspired and all cell pellets were resuspended in 1 ml PBS. Single cell suspensions 
(106 cells/ml) were transferred to FACS tubes (Abdool et al.) for FACS analysis. Spenocytes, 
lymph node cells and bone marrow cells were maintained in RPMI-complete medium and 
observed for outgrowth of cells lines for further analysis.  
2.6.4. Injection of Abelson transformed bone marrow B-cell lines into 
Rag2-/- γc-/- mice 
For tail vein injection 1x105 v-abl transformed cells were resuspended in 100 µl PBS and 
injected via tail vein into immuno-compromised Rag2-/-γc-/- mice. The recipients were 
checked daily for disease onset. Diseased mice were sacrificed by cervical dislocation and 
blood samples were taken for blood smears and FACS analysis. Spleens and lymph nodes 
were excised and analysed for their weight and FACS analysis. For further histological 
analysis pathological sections of the spleen, liver and lymph nodes were taken and kept in 4% 
formaldehyde (Sigma) for 2 days and afterwards stored in PBS at 4°C. 
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Furthermore the isolated organs were treated as described above to obtain single cell 
suspensions for FACS analysis. 
2.7. Statistical analysis 
For statistical analysis GraphPad Prism software was used. Statistics were calculated using an 
unpaired t-test (mean values represent data ± SEM). The log rank test was used to analyze 
differences in the Kaplan-Meier plot for statistical significance. 
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3. Results 
3.1. Newborn infections of IFNAR1fl/flCD19cre+ and IFNAR1fl/flCD19cre- 
mice appear to result in faster progression of B-lymphoid leukemia 
in IFNAR1fl/flCD19cre+ mice 
Previous data in our lab have shown that mice impaired in type I IFN signaling succumbed to 
B-lymphoid leukemia significantly earlier than their control animals. Since leukemia 
formation is a complex process between tumorigenic and immune cells, we addressed the 
question, whether the higher susceptibility to B-lymphoid leukemia is due to a tumor cell 
intrinsic effect or due to a defect in the immune defense. Therefore, we bred IFNAR1fl/fl mice 
with CD19cre+ mice, to delete the IFNAR1 receptor chain specifically in B-lymphocytes.  
Due to the fact that newborn mice do not have a fully developed immune system, we 
challenged them with A-MuLV (as described in materials and methods) to induce a slowly 
developing leukemia. The infected mice were examined daily for signs of disease and 
diseased mice were sacrificed.  
Interestingly, IFNAR1fl/flCD19cre+ mice (n=8) succumbed to B cell leukemia with shortened 
latency when compared to their control littermate IFNAR1fl/flCD19cre- mice (n=8), although 
it does not reach the criteria of statistical significance (log rank-test, n.s, p<0.2458) (Figure 
11A).  
As mentioned above, B-cell specific deletion of the IFNAR1 receptor chain was achieved by 
crossing IFNAR1fl/fl mice with mice expressing the cre recombinase under the B-cell specific 
CD19 promotor. To test for the deletion, splenocytes of the IFNAR1fl/fl CD19cre+ mice were 
cultured and DNA was isolated to perform PCR analysis. As shown in Figure 11B, the 
deletion of the floxed gene results in a 339bp fragment, whereas DNA of 
IFNAR1fl/flCD19cre- cells gives rise to an 1160bp fragment in gel electrophoresis. 
As mentioned above, diseased mice were sacrificed and the isolated hematopoietic organs 
were analyzed carefully, including the determination of the spleen weight and lymph node 
weight. As shown in Figure 12A, IFNAR1fl/flCD19cre+ mice displayed significantly increased 
spleen weights compared to their IFNAR1fl/flCD19cre- littermate controls (unpaired t test, *, 
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p< 0.0351). Furthermore, we found that isolated lymph nodes displayed a slightly increased 
weight without reaching the criteria of being statistically significant (unpaired t test, p< 0.05).  
In order to verify the leukemia of these mice, bone marrow cells, splenocytes, lymph node 
and peripheral blood cells were isolated and analyzed according to their surface marker 
expression. FACS analysis confirmed that these mice suffered from a B-lymphoid leukemia, 
as all hematopoietic organs were infiltrated with B220+, CD43+ and CD19+ tumor cells (see 
Figure 12B and 13B). The expression levels of B-lymphoid markers varied among the 
individual examined mice. To elucidate the actual IFNAR1 expression on B cells we 
performed FACS analysis and showed that IFNAR1fl/flCD19cre- mice, which died later (e.g. 
mouse D11459, red peak in Figure13C) express more of the IFNAR1 receptor chain than 
mice that died earlier (e.g. mouse D11451, green peak in Figure 13C). We further 
characterized leukemic cells by doing Hematoxylin and Eosin (H&E) stainings of blood 
smears and histological sections of the spleen. As illustrated in Figure 13A1+A2 and Figure 
12C1+C2 both genotypes did not show significant differences in white blood cell numbers 
and the infiltration of tumor cells. 
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Figure 11. Challenge of newborn IFNAR1fl/flCD19 cre+ and IFNAR1fl/flCD19 cre- mice with the murine 
oncogene v-abl results in slightly earlier onset and progression of B-lymphoid leukemia.  (A) The survival 
of newborn mice is depicted in the Kaplan-Meier plot (log rank test, n.s. p<0,2458). (B) PCR amplification of 
genomic DNA isolated from IFNAR1fl/flCD19cre+ cells resulted in a 339 bp fragment devoid of the loxP flanked 
fragment, whereas genomic DNA from IFNAR1fl/flCD19cre- cultured cells gave rise to a 1160 bp fragment. In 
order to ensure the deletion of the floxed IFNAR1 gene in diseased IFNAR1fl/flCD19cre+ mice, PCR was 
performed, amplifying the floxed gene in case of genomic DNA isolated from IFNAR1fl/flCD19cre- cells but not 
in case of IFNAR1fl/flCD19cre+ cells. Appropriate controls are also shown.  
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Figure 12 The infiltration of leukemic cells is comparable in IFNAR1fl/flCD19cre+ mice and 
IFNAR1fl/flCD19cre- mice. (A) Determination of the spleen weight of the indicated genotypes revealed a 
significantly increased spleen weight in IFNAR1fl/flCD19cre+ mice. No significant difference was observed in 
the lymph node weight. (B) Statistical analysis of B220+CD19+CD43+ cell populations showed no significant 
differences among both genotypes in bone marrow, spleen and lymph nodes. (C) Representative Hematoxylin 
and Eosin stained spleen sections of diseased mice are shown. 
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Figure 13. Characterization of leukemic cells derived from IFNAR1fl/flCD19cre+ and IFNAR1fl/flCD19cre- 
mice. (A1,2) Hematoxylin and Eosin (H&E) staining of blood smears showed no significant differences in white 
blood cell numbers among both genotypes. (B) Living cells were gated for the B220+ fraction and subsequently 
analyzed for surface expression of CD19+ and CD43+ B-cell markers. Percentages indicate CD19+/CD43+ 
populations. One representative FACS plot for IFNAR1fl/flCD19cre+ and IFNAR1fl/flCD19cre- is shown. (C) 
FACS analysis for IFNAR1 receptor chain expression on B cells. IFNARfl/flCD19cre- mice that died earlier 
expressed less of IFNAR1. Two representative histograms of each genotype are shown.  
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Taken together, the data obtained from the newborn infection experiment demonstrate that 
IFNAR1fl/flCD19cre+ mice are more prone to develop Abelson induced B cell leukemia, 
which indicates that the faster progression of B-lymphoid leukemia is due to a tumor cell 
intrinsic effect. 
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3.2. Wildtype tumor cells do not produce low levels of IFN-β  ex vivo and 
in vitro 
As mentioned above, previous data obtained from newborn infections and transplantation 
experiments in immuno-compromised mice showed that either infection with A-MuLV of 
mice with impaired type I IFN signaling or injection of v-abl transformed IFNAR1-/- and 
IFNβ-/- cells into Rag2-/- mice resulted in faster progression of B-lymphoid leukemia 
compared to the wild type. To elucidate the mechanism underlying the increased 
susceptibility of IFN-β-/- and IFNAR1-/- mice to B-lymphoid leukemia, we investigated 
whether this effect might be due to a tumor cell intrinsic effect or due to a defect in the 
immune system. 
As outlined in the introduction, IFN-β has anti-tumor activity. It has been shown that IFN-β 
inhibits tumor growth. Therefore, it is possible that Abelson transformed cells also produce 
IFN-β and thereby limit their own growth. We therefore investigated the IFN-β levels from 
stable pro-B-cells transformed with v-abl. Different IFN-β levels in the tumor cells might be 
an explanation for the differences in latency in transplanted Rag2-/- animals. 
To verify the level of IFN-β production of v-abl transformed pro B-cell lines in vivo, we 
injected 106 v-abl transformed wt and IFNβ-/- cells subcutaneously into Rag2-/-γc-/- mice. 
After 10 days, mice were sacrificed and solid tumors were isolated. Single cell suspension of 
tumor material was prepared and protein lysates were performed as described in materials and 
methods for Western blot analysis. 
As outlined in the introduction production of IFN-β leads to JAK/STAT signaling and thereby 
phosphorylation of STAT2. Hence western blot analysis for phospho-STAT2 (p-STAT2) was 
performed. As illustrated in Figure 14A STAT2 was activated in isolated tumor samples 
injected with wt tumor cells, which indicates that the tumor cells produce type I IFNs that 
induce JAK/STAT signaling. But also tumor samples injected with IFN-β-/- tumor cells 
revealed p-STAT2 in Western blot analysis. This might be due to infiltrating cells that 
produce type I IFNs and therefore activate STAT2. 
To test the level of IFN-β production of leukemic cell lines in vitro, we performed qRT-PCR 
analysis with v-abl transformed wt and IFN-β-/- cell lines. As shown in Figure 14B, there was 
no increased expression of IFN-β in v-abl transformed wt cell lines (n=4) compared to IFN-β-
/- (n=2) and IFNAR1-/- (n=3) cell lines.  
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In conclusion, we could not detect constitutive expression of low levels of IFN-β neither ex 
vivo nor in vitro. Thus we could not prove our hypothesis that wt tumor cells produce IFN-β 
that delays tumor progression. The obtained results indicate that the longer latency of Rag2-/- 
mice injected with wt tumor cells is not due to their IFN-β production.  
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Figure 14. No difference in the IFN-β  expression levels of tumor cells. (A) Rag2-/-γc-/- mice were injected 
subcutaneously with various v-abl transformed cell lines and solid tumors were isolated. Western blot analysis 
for phospho-Stat2 (p-Stat2) did not show any differences in the phosphorylation levels of Stat-2 between wt 
(n=4) derived and IFN-β-/- (n=2) derived tumors. Control immunoblots with anti-STAT2, anti-STAT1 and anti-
α-Tubulin-antibodies are shown. (B) qRT-PCR for the IFN-β gene also demonstrated that there are no detectable 
levels of IFNβ in v-abl transformed wt (n=4) cell lines compared to IFNAR1-/- (n=3) and IFN-β-/- (n=2) cell 
lines. Raw 264.7 cells (R.c) and Raw 264.7 cells stimulated with LPS (R.c+LPS) were used as positive controls 
in both experiments. 
Results 
42 
3.3. V-abl transformed wt and IFNAR1-/- cells display comparable 
tumorigenicity in Rag2-/-γc-/- mice 
Previous data in our lab have shown that Rag2-/- mice challenged with IFNAR1-/- or IFN-β-
/- leukemic cell lines succumb to B-lymphoid leukemia significantly faster than Rag2-/- mice 
challenged with wt leukemic cell lines. As Rag2-/- mice lack B- and T-cells but not Nk cells, 
this effect might be due to recognition by Nk cells, which are important mediators in tumor 
surveillance. To test whether Nk cells play a role in our B cell leukemia model, we performed 
bone marrow transplantation of leukemic cells into Rag2-/-γc-/- mice. Rag2-/-γc-/- mice not 
only lack functional B-, and T-lymphocytes but also Nk cells (Mazurier et al., 1999). Hence, 
Rag2-/-γc-/- mice are particularly suited to study the onset of lymphoid leukemia because cell 
autonomous properties are not affected by a functional immune system.  
To study the effect of v-abl transformed cell lines in immuno-compromised mice, 8 Rag2-/-γc-
/- mice were challenged with 105 leukemic cells via tail vein injection. Two independently 
established wt and IFNAR1-/- cell lines were injected at least in two recipient mice. Prior to 
injection, the proliferation rate of the cell lines was determined by a 3H-thymidine 
incorporation assay. The 3H-thymidine incorporation experiment showed that the cell lines 
used were comparable in their proliferation rate in vitro (Figure 15A). Thus differences in the 
latency of injected mice is not due to a proliferative advantage. Furthermore cell lines were 
controlled for surface expression of B-lineage markers by FACS analysis before injection. All 
cell lines were gated for B220+ and subsequently analyzed for CD19+ and CD43+ surface 
marker expression. In all cases we obtained homogenous populations of B220+CD19+CD43+ 
B-lymphocytes (Figure 15B). Additionally, we confirmed the genotype of the recipient mice. 
Therefore, we analyzed one healthy wt, Rag2-/- and Rag2-/-γc-/- mouse, respectively, for the 
Nk cell surface markers NK1.1 and DX5. The wt, Rag2-/- and Rag2-/-γc-/- mice were 
sacrificed and the spleens were isolated to test for numbers of CD3-DX5+NK1.1+ cells. As 
shown in Figure 15C only 0.1% of CD3-DX5+NK1.1+ cells were detected in Rag2-/-γc-/- mice 
compared to 6.7% in wt mice and 64.4% in Rag2-/- mice. 
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Figure 15. V-abl transformed cell lines were comparable in their proliferation rate and showed typical B 
cell markers. (A) A 3H-thymidine incorporation assay was performed to determine the proliferation rate of  six 
independently established cell lines. The proliferation among the cell lines was comparable. (B) FACS analysis 
of tumor cell lines. All used cell lines were gated for B220+ cells and subsequently analyzed for surface 
expression of CD19+ and CD43+ B-cell markers. Characterization of the cell lines revealed a homogenous 
population of B220+CD19+CD43+ B-lymphocytes. (C) FACS immuno phenotyping of healthy mice was 
performed to test for Nk cell numbers of Rag2-/-γc-/- mice. Splenocytes were gated for CD3- cells and 
subsequently analyzed for surface expression of NK1.1+ and DX5+. Only 0.1% of a CD3-NK1.1+DX5+ cell 
population was detected in Rag2-/-γc-/- mice. Wt and Rag2-/- mice were used as controls.  
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Transplanted mice were examined daily for signs of disease. As soon as mice appeared sick 
they were sacrificed. After 16 days, the first Rag2-/-γc-/- mouse that had received v-abl 
transformed wt cells showed severe symptoms of leukemia. All recipients of v-abl 
transformed wt cells (n=4) died between day 16 and day 20 (mean survival: 17 days). Mice 
that received v-abl transformed IFNAR1-/- cells (n= 4) died between day 18 and day 27 
(mean survival: 18.5 days). The disease latency of both groups was comparable as shown in 
Figure 16A ( wt vs. IFNAR1-/- → log rank test, n.s. p< 0.2286).  
In order to verify B-lymphoid leukemia single cell suspensions of bone marrow and spleen 
were analyzed according to the surface expression of B-lineage markers by FACS as 
described in materials and methods. All hematopoietic organs were infiltrated with B220+, 
CD43+ and CD19+ tumor cells and were therefore classified as B-lymphoid tumors. The 
expression levels of B-lymphoid markers varied among the individual examined mice (Figure 
16B).  
Comparison of the spleen weights (Figure 16C) showed that spleens of Rag2-/-γc-/- mice 
injected with v-abl transformed wt cells had a slightly increased spleen weight without 
reaching the criteria of being statistically significant compared to mice injected with v-abl 
transformed IFNAR1-/- cells (wt → mean: 0.54 ± 0.047 g; IFNAR1-/- → mean: 0.48 ± 0.02 
g).  
These results indicate that type I IFN signaling is important for Nk cell mediated tumor 
surveillance. Similar results were obtained in three independently performed experiments. 
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Figure 16. V-abl transformed wt and IFNAR1-/- bone marrow cells induce a comparably progressing 
leukemia in Rag2-/-γc-/- mice. (A) The survival of recipient mice is depicted in the Kaplan-Meier plot (wt vs. 
IFNAR1-/- → log rank test, n.s. p< 0.2286). (B) Statistical analysis of B220+CD19+CD43+ cell populations 
showed no significant differences in bone marrow and the spleen. (C) Determination of the spleen weight of the 
indicated genotypes revealed no significant differences. 
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3.4. Type I IFN signaling plays a role in angiogenesis 
As outlined in the introduction, several studies have demonstrated the anti-angiogenic 
function of IFNs. Thereby IFNs inhibit the production of angiogenic growth factors, such as 
basic fibroblast growth factor (bFGF) (Singh et al., 1995) or vascular endothelial growth 
factor (VEGF) (Rosewicz et al., 2004). Since it is known that angiogenesis is not only crucial 
in solid tumor formation but also in the pathogenesis of hematologic malignancies and 
metastatic spread throughout the lymphatic vasculature (Podar et al., 2005), one aim of this 
master thesis was to investigate the role of type I IFN signaling in angiogenesis during v-abl 
induced leukemia progression. 
When we injected v-abl transformed IFNAR1-/- and IFNβ-/- bone marrow cell lines 
subcutaneously into Rag2-/-γc-/- mice, we observed tumors, in which the blood supply was 
more efficient than in tumors evoked by wt leukemic cell lines (shown in Figure 17A). The 
increased vascularization of tumors deficient for IFN-β and IFNAR1 was confirmed by 
Periodic acid Schiff (PAS) staining of histological sections (Figure 17D). Thus we addressed 
the question whether our v-abl transformed bone marrow cell lines express VEGF. To 
respond to this question we performed qRT-PCR analysis, as described in materials and 
methods. As shown in Figure 17B the expression levels of VEGF-A seem to be more than 
five times increased in IFNβ (n=3) and IFNAR1 (n=2) deficient cell lines compared to wt 
controls (n=7). However, due to the high standard deviation, which indicates a high variance 
of expression levels among cell lines of the same genotype, data did not reach the criteria of 
being statistically significant (One-way ANOVA→ n.s., p< 0.5276).  
In addition we performed scratch assays as described in materials and methods. As shown in 
Figure 17C epithelial cells cultured for 24 hours in the supernatant of v-abl transformed IFN-
β-/- cell lines migrated significantly faster to close the scratch than the wt control (wt vs. IFN-
β-/- → unpaired t test, *, p< 0.015). Migration of endothelial cells cultured in the supernatant 
of IFNAR1-/- tumor cell lines also yielded in faster disappearance of the scratch compared to 
the wt control but without being statistically significant (wt vs. IFNAR1-/- → unpaired t test, 
n.s., p< 0.0613).  
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Figure 17. Type I IFNs display an inhibitory effect on angiogenesis. (A) S.c. injection of IFN-β-/- and 
IFNAR1-/- tumor cells into Rag2-/-γc-/- mice yielded in tumors with increased blood vessels compared to wt 
controls. (B) To test for the relative gene expression of VEGF-A in vitro, qRT-PCR was performed. (C) Scratch 
assays revealed that epithelial cells cultured for 24 hours in the supernatant of v-abl transformed IFN-β-/- and 
IFNAR1-/- cell lines migrated faster to close the scratch than the wt control. One experiment out of two is 
shown. Data are summarized in the right panel. (D) Histological Periodic acid-Schiff (Mes-Masson et al.) 
stainings of tumor samples confirm the increased vascularization in knock out tumors compared to wt tumors. 
One representative example of each genotype is shown. 
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To further analyze the impact of type I IFNs on angiogenesis in the Abelson tumor model we 
performed an Oligo GEArray for angiogenesis (see Figure 18) as described in materials and 
methods. Two independently established cell lines of each genotype were used. Table 4 and 
Table 5 summarize the genes up- and down-regulated in v-abl transformed knock out bone 
marrow cell lines compared to wt controls. 
Abbrevation Up-regulated genes Fold difference Abbrevation Down-regulated genes 
Fold 
difference 
CCl 11 Small chemokine (C-C motif) ligand 11 2.2 Adra2b 
Adrenergic receptor, 
alpha 2b 0.37 
PDGF-B Platelet derived growth factor, B polypeptide 33.4 Bai1 
Brain-specific 
angiogenesis inhibitor 1 0.21 
CxCl 1 Chemokine (C-X-C motif) ligand 1 51.8 Cxcl10 
Chemokine (C-X-C motif) 
ligand 10 0.18 
   Efna2 Ephrin A2 0.28 
   Il12a Interleukin 12A 0.47 
   Ptgs1 
Prostaglandin-
endoperoxide synthase 1 0.64 
   Ptn Pleiotrophin 0.04 
   Tgfb3 
Transforming growth 
factor beta 3 0.22 
   Tnf Tumor necrosis factor 0.15 
   Vegfb 
Vascular endothelial 
growth factor B 0.15 
   Vegfc 
Vascular endothelial 
growth factor C 0.23 
Table 4. Up- and down-regulated genes in v-abl transformed IFNAR1-/- bone marrow cell lines compared 
to wt controls. The mean of two different cell lines used is shown. 
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Abbrevation Up-regulated genes Fold difference Abbrevation Down-regulated genes 
Fold 
difference 
Adra2b Adrenergic receptor, alpha 2b 1.82 Il12a Interleukin 12A 0.53 
Vegfc Vascular endothelial growth factor C 15.73 Ptn Pleiotrophin 0.61 
   Tgfb3 Transforming growth factor beta 3 0.33 
Table 5. Up-and down-regulated genes in v-abl transformed IFN-β-/- bone marrow cell lines. The mean of 
two different cell lines used is shown. 
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Figure 18. Oligo GEArray analysis revealed several genes involved in angiogenesis, which are up- and 
down-regulated in v-abl transformed IFN-β-/- and IFNAR1-/- bone marrow cell lines. (A) OligoGEArray 
membranes for each genotype were analysed using the GEArray expression analysis suite 2.0. (B) Scatter plot of 
IFN-β-/- cell lines compared to wt controls. (C) Scatter plot of IFNAR1-/- cell lines compared to wt controls. 
Up-regulated genes are indicated with red crosses and down-regulated genes are indicated with green crosses.  
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Oligo GEArray analysis shows that PDGF-B and CxCl1 was up-regulated in v-abl 
transformed IFNAR1-/- bone marrow cell lines. In IFN-β knock out tumor cell lines Vegfc 
was shown to be up-regulated. In case of IFNAR1 knock out tumor cell lines pleiotrophin was 
strongly down-regulated, however the expression levels of the genes listed above vary among 
the different cell lines of the same genotype. Therefore we compared each cell line alone to 
the wt control and found that in all the knock out tumor cell lines Il12a, pleiotrophin and 
Tgfb3 are consistently down-regulated. Thus it will be interesting to focus on these three 
genes in our further studies to test whether type I IFN signaling has an impact on them. 
Taken together, all of the experiments we have done indicate that IFN-β has an anti-
angiogenic effect and that type I IFN signaling has an inhibitory function in angiogenesis. 
Further experiments have to be done to identify genes affected by type I IFN signaling and the 
mechanism underlying the inhibitory function of type I IFNs in angiogenesis. 
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4. Discussion 
As outlined in the introduction type I IFNs have been shown to play a crucial role in anti-viral 
defense as well as in cancer immunoediting. In case of viral infections of a host, type I IFNs 
are produced by infected cells and cells involved in the innate and adaptive immune response 
(Vilcek, 1996). Thus it was shown that IFNs play an important role in bridging the innate and 
the adaptive immune system (Swann et al., 2007). In addition to their anti-viral activity it has 
been shown recently that IFNs have a critical role in the elimination phase of cancer 
immunoediting by promoting host antitumor immunity (Dunn et al., 2006). The anti-
proliferative nature of IFNs, as well as the fact that they are supposed to inhibit the production 
and release of pro-angiogenic factors from tumor cells or lymphocytes, makes them also 
possible inhibitors of angiogenesis (Sidky et al., 1987). 
In this study, we used v-abl induced B-lymphoid leukemia as a model system to mimic human 
leukemia formation in mice and to further analyze the impact of impaired type I IFN signaling 
on leukemia formation. It has been shown previously in our lab that IFNAR1-/- and IFN-β-/- 
mice injected with the Abelson Murine Leukemia Virus (A-MuLV) succumbed to B-
lymphoid leukemia significantly faster than their wt controls. The obtained results prompted 
us to examine whether this phenotype was due to a direct tumor cell intrinsic effect or due to 
an indirect defect in the immune response. To do so, we used IFNAR1fl/flCD19cre+ mice to 
delete the IFNAR1 receptor chain of the type I IFN receptor specifically in B-lymphocytes. 
As described above, A-MuLV is a replication incompetent retrovirus that targets B-cells in 
vivo. Injection of newborn IFNAR1fl/flCD19cre+ mice and littermate controls with A-MuLV 
yielded in an accelerated B-lymphoid leukemia formation in IFNAR1fl/flCD19cre+ mice. 
However, the difference in latency did not reach the criteria of statistical significance. 
Inefficient deletion of the IFNAR1 chain in the IFNAR1fl/flCD19cre+ mice could be excluded 
by PCR of isolated tumor cells. Interestingly, when we tested for the expression of IFNAR1 
on the tumor cells of the diseased mice by FACS analysis, we found a correlation between 
IFNAR1 expression levels and disease latency. IFNAR1fl/flCD19cre- mice that succumb to B 
cell leukemia with a longer latency display higher expression levels of IFNAR1 on their 
tumor cells than mice that died earlier. IFNAR1fl/flCD19cre+ mice consistently did not 
express IFNAR1 on the tumor cells. To confirm the correlation between disease latency and 
expression levels of IFNAR1 on leukemic cells, we certainly will have to transplant tumor 
cells expressing high or low levels of IFNAR1 or no IFNAR1 at all into wild type recipient 
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mice. If our assumptions are true, mice that receive tumor cells not expressing IFNAR1 again 
will lead to the faster progressing leukemia, whereas mice that are transplanted with tumor 
cells displaying high levels of IFNAR1 will be the last mice to die from leukemia. 
Several groups have demonstrated that the presence of a constitutive low level of type I IFN 
in mouse embryonic fibroblasts (MEFs), splenocytes and bone marrow cells, plays a role in 
the regulation of the adaptive immune response (Bocci et al., 1985);(Tovey et al., 
1987);(Taniguchi et al., 2001). Previous data from our lab showed that Rag2-/- mice injected 
with v-abl transformed IFN-β-/- and IFNAR1-/- bone marrow cell lines succumb to B-
lymphoid leukemia significantly faster than wt controls. We therefore hypothesized that v-abl 
transformed wt cells might also produce a constitutive low amount of IFN-β and thereby 
inhibit their own tumor progression. To verify low levels of IFN-β produced by v-abl 
transformed wt cells we did Western blot analysis for p-STAT2 of tumor samples derived 
from Rag2-/-γc-/- mice injected with v-abl transformed wt and IFN-β-/- bone marrow cell 
lines. STAT2 as one component of the transcription factor complex ISGF3 is exclusively 
phosphorylated upon type I IFN signaling. Therefore, detection of p-STAT2 would indicate 
type I IFN signaling as a response to IFN-β production. We could observe p-STAT2 in three 
of four wt tumor samples, however also in one IFN-β-/- tumor sample. This could be due to 
infiltrating cells that migrate into the tumor and produce type I IFNs. Alternatively, we tested 
for constitutive low levels of IFN in our v-abl transformed bone marrow cell lines in vitro. To 
do so, we did quantitative RT-PCR for the IFNβ gene. However, we failed to detect a 
constitutive low level of IFN-β directly in v-abl transformed wt cells. It is possible that these 
techniques were not sensitive enough to detect low levels of IFN-β produced by tumor cells. 
Taken together, so far our data do not support the hypothesis that the phenotype observed in 
the transplantation experiments mentioned above was due to IFN production by tumor cells.  
An evolving tumor is constantly confronted with the immune system that can detect and 
eliminate transformed cells. To determine whether the phenotype is due to tumor cell intrinsic 
properties that lead to a defective immune response, transplantation experiments with 
immuno-deficient Rag2-/-γc-/- mice were performed. Due to the fact that those mice do not 
have any B-, T- and Nk cells, respectively, tumor cell autonomous properties are not affected 
by cellular mediators of the immune system. We could show that recipient mice injected with 
wt and IFNAR1-/- tumor cells succumbed to B-lymphoid leukemia with comparable latency. 
This finding suggests that type I IFN signaling is important in Nk cell activation and further 
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leukemia progression. However, to investigate the importance of type I IFN signaling for Nk 
cell mediated surveillance of Abelson-induced leukemia additional experiments need to be 
performed   
As mentioned above IFNs have a crucial role in bridging the innate and the adaptive immune 
system, for example by enhancing effects on Nk cell activity (reviewed in Bellardelli F., 
2002) In our laboratory it has been shown that Nk cells are the key mediators of tumor 
surveillance of Abelson induced leukemia (Stoiber et al., 2004). To investigate whether 
deficiency in type I IFN signaling leads to a defect in Nk cell cytotoxicity we will cross 
IFNAR1fl/fl mice with NKcre+ mice (that were generated in our laboratory). With these mice 
will test whether Nk cell impaired in type I IFN signaling show differences in proliferation 
compared to wt Nk cells by 3H-thymidin incorporation assays or CFSE labeling assays. In 
addition, defects in Nk cell effector functions could be elucidated by performing 51chromium 
release assays to test the capacity of their cytotoxicity, as well as cytokine secretion such as 
IFN-γ. 
During this study we stroke a new path to elucidate the role of type I IFN signaling in v-abl 
induced leukemia. We could show that v-abl transformed IFN-β and IFNAR1 knock out bone 
marrow cell lines had an increased expression level of VEGF compared to wt controls. Due to 
the fact that several studies have demonstrated that IFNs exhibit an anti-angiogenic function 
by inhibiting the production of angiogenic growth factors, such as basic fibroblast growth 
factor (bFGF) (Singh et al., 1995) or vascular endothelial growth factor (VEGF) (Rosewicz et 
al., 2004) we decided to extend our study to the effect of type I IFNs on angiogenesis. We 
could demonstrate that subcutaneous injection of v-abl transformed knock out bone marrow 
cell lines yielded in tumors with a better blood supply than wt controls in Rag2-/-γc-/- mice. 
These results indicate that type I IFN signaling is involved in the process of vascularization, 
which could be also confirmed by scratch assays. We further performed Oligo GEArrays for 
angiogenesis that resulted in a set of genes, which might be affected by impaired type I IFN 
signaling. We could show in IFN-β knock out tumor cell lines that Vegfc is strongly up-
regulated, which recapitulates the data obtained by qRT-PCR. Even though we obtained 
various gene expression among the samples of the same genotype we detected that Il12a, 
pleiotrophin and Tgfb3 are consistently down-regulated in each cell line. As it has been 
shown that IL-12 is effective in antitumor response by suppressing the development of new 
blood vessels (Sorensen et al., 2010), down-regulation of Il-12A in IFNAR1 and IFN-β knock 
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out cell lines is another hint that type I IFN signaling has a regulatory function in 
angiogenesis. Interestingly, pleiotrophin is reported to promote tumorgenesis and 
angiogenesis (Laaroubi et al., 1994, Fang et al., 1992). In addition it has been shown that 
Tgfb3 might play a protective role against tumorgenesis in skin, breast, oral and gastric 
mucosa (Laverty et al., 2009). It is conceivable that functional type I IFN signaling is needed 
for up-regulation of pleiotrophin and Tgfb3 in tumor cells. We will have to perform additional 
qRT-PCR with more v-abl transformed bone marrow cell lines to confirm the obtained 
phenotype in this experiment. Furthermore we could inject knock out tumor cell lines 
subcutaneously into Rag2-/-γc-/- mice and inject Il12 into the tumor to study if additional Il12 
can block vascularization and reverse the phenotype we observed during this master thesis. 
Taken together this work demonstrates the importance of type I IFN signaling in tumor 
progression. The obtained data indicate that an interplay of a tumor cell intrinsic effect and a 
defect in immune response is responsible for the obtained phenotype during this study.  
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6. Abbrevations 
ALL acute lymphoblastic leukemia 
A-MuLV Abelson induced mouse leukemia virus 
BCR breakpoint cluster region 
bp base piar 
c-abl cellular Abelson proto-oncogene 
CML chronic myeloid leukemia 
DC dentritic cell 
DMEM Dulbecco's modified eagle medium 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
EDTA ethylenediaminetetaacid 
FACS flourescence activated cell sorting 
FCS fetal calf serum 
FGF fiboblast growth factor 
GAS interferon gamma activated sequence 
IFN interferon 
IFNAR interferon alpha/beta receptor 
IFNAR1 interferon alpha/beta receptor chain 1 
IFNAR2 interferon alpha/beta receptor chain 2 
IFN-α interferon alpha 
IFN-β interferon beta 
IFN-γ interferon gamma 
Abbrevations 
65 
IRF interferon regulatory factor 
ISG interferon stimulated gene 
ISGF3 interferon stimulated gene factor 3 
ISRE interferon stimulated response element 
JAK janus kinase 
JAK1 janus kinase 1 
kDa kilo Dalton 
MCA methylcholanthren 
Mda5 melanoma differentiation associated gene 5 
MEF mouse embryonic fibroblast 
Mo-MuLV Moloney murine leukemia virus 
Nk cell natural killer cell 
n.s. not significant 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGF platelet derived growth factor 
PIAS protein inhibitor of activated STAT 
Ptn pleiotropin 
Rag2 recombinase activating gene 2 
RIG-I retinoic acid-inducible gene 1 
rpm rotation per minute 
SDS sodium dodecyl sulphat 
SHP 
SH-2 domain-containing protein tyrosine 
phosphatase 
Abbrevations 
66 
SOCS suppressor of cytokine signaling 
STAT1 
signal transducer and activator of 
transcription 1 
STAT2 
signal transducer and activator of 
transcription 2 
TLR toll-like receptor 
TYK2 tyrosine kinase 2 
v-abl viral Abelson oncogene 
VEGF vascular and endothelial growth factor 
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Education	   	  
Since	  Jan.	  2009	  
(final	  exam:	  
March	  	  2010)	  
Medical	  University	  of	  Vienna	  –	  Diploma	  thesis:	  “The	  role	  of	  type	  I	  
interferon	  in	  V-­‐abl	  induced	  leukemia”	  in	  the	  group	  of	  Dr.	  Dagmar	  Stoiber-­‐
Sakaguchi	  /	  Prof.	  Dr.	  Veronika	  Sexl	  	  
	  
 Performed	   intravenous	   injections,	   intra	   peritoneal	   injections,	  
subcutaneous	  injections	  and	  newborn	  injections	  in	  the	  mouse	  model	  
system	  
 Skilled	  in	  cell	  tissue	  culture,	  retroviral	  transfections,	  protein	  methods,	  
DNA	  and	  RNA	  methods,	  FACS	  analysis	  and	  MACS	  cell	  separation	  
 Skilled	   operator	   of	   BD	   FACS	   Calibur	   system,	   RT-­‐PCR,	   Eppendorf	  
Mastercycler	  
	  
Since	  2004	   University	  of	  Vienna	  –	  Study	  of	  Biology,	  specialized	  in	  Molecular	  genetics	  
and	  pathologies,	  Immunology	  and	  Microbiology	  
1996-­‐2004	   Gymnasium	  Werndlpark,	  Leopold-­‐Werndl	  Straße	  5,	  4400	  Steyr, focusing	  
on	  biology	  and	  English,	  graduation	  with	  distinction	  
1992-­‐1996	   Primary	  school	  Promenade	  1-­‐	  Dr.	  Rudolf	  Kirchschläger-­‐Schule,	  4400	  
Steyr	  
Internships	   	  
Summer	  term	  
2007/2008,	  
winter	  term	  
2009	  
University	  of	  Vienna,	  tutor	  of	  undergraduate	  students	  in	  the	  organic	  
chemistry	  lab	  
 Performed	  synthesis	  of	  peptides	  and	  carbohydrates	  
 Performed	  isolation	  of	  natural	  products	  
	  Conference	  
contributions	  
	  
September	  
2009	  
	  
	  
February	  2010	  
7th	  International	  Symposium	  on	  the	  biology	  of	  endothelial	  cells,	  
Vienna,	  Austria	  
Title	  of	  presented	  poster:	  “Role	  of	  type	  I	  interferon	  signaling	  in	  tumor	  
development	  and	  angiogenesis” 
FEBS-­‐Special	  Meeting	  2010:Jak-­‐Stat	  Signalling:	  from	  Basics	  to	  Disease,	  
Vienna,	  Austria	  
Title	  of	  presented	  poster:	  The	  role	  of	  type	  I	  Interferon	  in	  Abelson	  
induced	  leukemia 
	  
Name	   Nadine	  Moritz	   	  
Address	   Gentzgasse	  14-­‐20/11/23-­‐24	  
A-­‐1180	  Vienna,	  Austria	  
Telephone	   +43	  650	  9161824	  
Email-­‐Address	   nadine.moritz@meduniwien.ac.at	  
nadine-­‐moritz@gmx.at	  
	  
Publications	   	  
	  
Neugebauer	  N.,	  Moritz	  N.,	  Eckelhart	  E.,	  Simma	  O.,	  Müller	  M.	  ,	  Sexl	  V.	  
and	  Stoiber	  D.	  „	  The	  role	  of	  type	  I	  interferon	  in	  Abelson	  induced	  
leukemia“	  
Manuscript	  in	  preparation	  
Language	  and	  other	  skills	  
Languages	    German	  –	  native	  
 English	  –	  spoken	  -­‐	  excellent,	  written	  -­‐	  excellent,	  comprehension	  -­‐	  
excellent	  	  
 Italian	  –spoken	  –	  basic,	  written	  –	  basic,	  comprehension	  –	  basic	  
Technical	    Extensive	  knowledge	  of	  office	  tools	  and	  operating	  systems	  (Windows,	  
Ms	  Office)	  
 Experienced	  with	  a	  variety	  of	  biological	  software	  (DIVA,	  tScratch,	  EP	  
realplex)	  
	  
	  
	  
	  
	  
